Munro J F, MacCuish A C, Marshall A, Wilson E M, Duncan L J
Br Med J. 1969 Apr 5;2(5648):13-5. doi: 10.1136/bmj.2.5648.13.
A double-blind trial was carried out to assess the weight-reducing effect of the diguanides in 90 women with refractory obesity and normal oral glucose tolerance. The daily dosage of phenformin and metformin was increased at weekly intervals up to 300 mg. and 3 g. respectively, and patients were maintained at this dose or on the maximum they could tolerate without anorexia or other gastrointestinal side-effects. Seventy-seven completed the 16-week period of study. There was a statistically significant difference between the mean weight change of the control and the treated groups, but no difference between those treated by phenformin or metformin. The weight-losing influence of the diguanides appeared to be no longer significant after the twelfth week of treatment.
进行了一项双盲试验,以评估双胍类药物对90名难治性肥胖且口服葡萄糖耐量正常的女性的减肥效果。苯乙双胍和二甲双胍的每日剂量每周增加一次,直至分别达到300毫克和3克,患者维持在该剂量或能耐受的最大剂量,且无厌食或其他胃肠道副作用。77名患者完成了为期16周的研究。对照组和治疗组的平均体重变化之间存在统计学上的显著差异,但苯乙双胍或二甲双胍治疗的患者之间无差异。治疗12周后,双胍类药物的减肥作用似乎不再显著。